Axsome Therapeutics, Inc. (AXSM)
137.01
-4.68
(-3.30%)
USD |
NASDAQ |
Nov 16, 16:00
135.01
-2.00
(-1.46%)
After-Hours: 06:37
Axsome Therapeutics Shareholders Equity (Quarterly) : 105.43M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 105.43M |
| June 30, 2026 | 83.30M |
| March 31, 2026 | 54.59M |
| December 31, 2025 | 88.30M |
| September 30, 2025 | 73.73M |
| June 30, 2025 | 73.08M |
| March 31, 2025 | 53.20M |
| December 31, 2024 | 57.02M |
| September 30, 2024 | 92.90M |
| June 30, 2024 | 102.85M |
| March 31, 2024 | 144.04M |
| December 31, 2023 | 190.98M |
| September 30, 2023 | 269.51M |
| June 30, 2023 | 278.80M |
| March 31, 2023 | 111.81M |
| December 31, 2022 | 109.56M |
| September 30, 2022 | 157.36M |
| June 30, 2022 | 15.20M |
| March 31, 2022 | 14.70M |
| December 31, 2021 | 15.63M |
| September 30, 2021 | 42.72M |
| June 30, 2021 | 71.44M |
| Date | Value |
|---|---|
| March 31, 2021 | 96.29M |
| December 31, 2020 | 113.79M |
| September 30, 2020 | 135.26M |
| June 30, 2020 | 154.24M |
| March 31, 2020 | 156.16M |
| December 31, 2019 | 178.72M |
| September 30, 2019 | 6.823M |
| June 30, 2019 | 24.28M |
| March 31, 2019 | 17.37M |
| December 31, 2018 | 0.9379M |
| September 30, 2018 | 0.7428M |
| June 30, 2018 | 7.009M |
| March 31, 2018 | 12.59M |
| December 31, 2017 | 16.72M |
| September 30, 2017 | 16.84M |
| June 30, 2017 | 22.75M |
| March 31, 2017 | 29.28M |
| December 31, 2016 | 21.57M |
| September 30, 2016 | 28.18M |
| June 30, 2016 | 34.90M |
| March 31, 2016 | 41.23M |
| December 31, 2015 | 46.44M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Eli Lilly & Co. | 40.27B |
| Filana Therapeutics, Inc. | 57.98M |
| CorMedix, Inc. | 461.71M |
| Eloxx Pharmaceuticals, Inc. | 41.07M |
| Breakthrough Chemistry, Inc. | 0.8373M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 826.77M |
| Total Liabilities (Quarterly) | 721.34M |
| Debt to Equity Ratio | 2.127 |
| Current Ratio | 1.422 |
| Net Debt Paydown Yield | 0.00% |